간질환 진단 시장 규모, 점유율, 동향 분석 보고서 : 진단 기술별, 질환별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Liver Disease Diagnostics Market Summary

The global liver disease diagnostics market size was valued at USD 37.85 billion in 2024 and is expected to reach USD 66.40 billion by 2033, growing at a CAGR of 6.39% from 2025 to 2033. This market centers on innovative diagnostic tools that enable early detection and monitoring of liver conditions, supporting improved patient outcomes.

The growing emphasis on non-invasive testing methods and molecular diagnostics drives demand across clinical settings. These diagnostic solutions find application in identifying liver fibrosis, cirrhosis, hepatitis, and other liver-related disorders. Key contributors to this trend include the intensified efforts by leading companies to develop sensitive and rapid testing methods tailored for specific demographics, such as pregnant women and individuals living with HIV. Additionally, ongoing research and development aimed at creating accurate diagnostic systems is likely to improve timely diagnoses and patient outcomes. The introduction of innovative diagnostic approaches, along with shifts in lifestyle factors like increased alcohol consumption and poor dietary habits, is also projected to influence the liver disease diagnostics market positively.

A notable advancement in this field is the FDA's approval of the Xpert HCV test and GeneXpert Xpress System by Cepheid in June 2024. This authorization marks the first point-of-care hepatitis C RNA test, allowing healthcare providers to diagnose and treat hepatitis C during the same visit. The test provides results in approximately an hour using a fingertip blood sample and can be conducted in various settings, including substance use disorder treatment facilities, correctional facilities, syringe service programs, doctor's offices, emergency departments, and urgent care clinics. This development exemplifies the growing trend toward rapid, accessible, and patient-centered diagnostic solutions in liver disease care.

Advancements in biomarker discovery and molecular diagnostic methods have greatly advanced liver disease diagnostics. The use of next-generation sequencing (NGS) and liquid biopsy techniques offers clinicians more accurate and real-time understanding of liver conditions. These tools enable early detection of disease and personalized treatment approaches, which are vital because many liver disorders often progress without symptoms.

The increasing rate of liver diseases worldwide, caused by factors such as viral hepatitis, alcohol use, and non-alcoholic fatty liver disease (NAFLD), further drives market growth. Greater awareness about liver health and government efforts to improve diagnostic facilities also significantly contribute to broader market adoption. Moreover, the move toward outpatient care and point-of-care testing improves access, allowing for quicker interventions and easing the pressure on healthcare systems.

Overall, innovation in the liver disease diagnostics market is driven by the need for faster, more accurate, and less invasive testing methods. The introduction of rapid point-of-care platforms and advanced molecular techniques has transformed how liver diseases are detected and managed, enabling timely interventions and personalized treatment plans. Additionally, the integration of artificial intelligence is improving data interpretation and predictive capabilities, while portable diagnostic devices are increasing access to testing in underserved areas. These technological advancements collectively contribute to better patient outcomes and are expected to shape the future trajectory of the market.

Global Liver Disease Diagnostics Market Report Segmentation

This report forecasts revenue growth at global, regional & country levels and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For the purpose of this report, Grand View Research has segmented the global liver disease diagnostics market on the basis of diagnosis technique, disease, end use and region:

• Diagnosis Technique Outlook (Revenue, USD Million, 2021 - 2033)
• Laboratory Tests
• Imaging
• Endoscopy
• Biopsy
• Others
• Disease Outlook (Revenue, USD Million, 2021 - 2033)
• NAFLD
• NASH
• Fibrosis
• Cirrhosis
• HCC
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Laboratories
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
  • 1.2.1. Diagnosis Technique Segment
  • 1.2.2. Disease Segment
  • 1.2.3. End Use Segment
• 1.3. Information analysis
  • 1.3.1. Market formulation & data visualization
• 1.4. Data validation & publishing
• 1.5. Information Procurement
  • 1.5.1. Primary Research
• 1.6. Information or Data Analysis
• 1.7. Market Formulation & Validation
• 1.8. Market Model
• 1.9. Total Market: CAGR Calculation
• 1.10. Objectives
  • 1.10.1. Objective 1
  • 1.10.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Insights Landscape

Chapter 3. Global Liver Disease Diagnostics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising Prevalence of Liver Diseases
    • 3.2.1.2. Advancements in Diagnostic Technologies
    • 3.2.1.3. Increasing Awareness and Early Detection
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High Cost of Advanced Diagnostics
    • 3.2.2.2. Limited Awareness in Developing Regions
  • 3.2.3. Market opportunity analysis
• 3.3. Global Liver Disease Diagnostics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis

Chapter 4. Global Liver Disease Diagnostics Market: Diagnosis Technique Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Liver Disease Diagnostics Market Diagnosis Technique Movement Analysis
• 4.3. Global Liver Disease Diagnostics Market Size & Trend Analysis, by Diagnosis Technique, 2021 to 2033 (USD Million)
• 4.4. Imaging
  • 4.4.1. Imaging market estimates and forecasts 2021 to 2033 (USD Million)
• 4.5. Laboratory Tests
  • 4.5.1. Laboratory Tests market estimates and forecasts 2021 to 2033 (USD Million)
• 4.6. Endoscopy
  • 4.6.1. Endoscopy market estimates and forecasts 2021 to 2033 (USD Million)
• 4.7. Biopsy
  • 4.7.1. Biopsy market estimates and forecasts 2021 to 2033 (USD Million)
• 4.8. Others
  • 4.8.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Global Liver Disease Diagnostics Market: Disease Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Liver Disease Diagnostics Market Disease Movement Analysis
• 5.3. Global Liver Disease Diagnostics Market Size & Trend Analysis, by Disease, 2021 to 2033 (USD Million)
• 5.4. NAFLD
  • 5.4.1. NAFLD market estimates and forecasts 2021 to 2033 (USD Million)
• 5.5. NASH
  • 5.5.1. NASH market estimates and forecasts 2021 to 2033 (USD Million)
• 5.6. Fibrosis
  • 5.6.1. Fibrosis market estimates and forecasts 2021 to 2033 (USD Million)
• 5.7. Cirrhosis
  • 5.7.1. Cirrhosis market estimates and forecasts 2021 to 2033 (USD Million)
• 5.8. HCC
  • 5.8.1. HCC market estimates and forecasts 2021 to 2033 (USD Million)
• 5.9. Others
  • 5.9.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Global Liver Disease Diagnostics Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Liver Disease Diagnostics Market End Use Movement Analysis
  • 6.2.1. Global Liver Disease Diagnostics Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 6.3. Hospitals
  • 6.3.1. Hospitals market estimates and forecasts 2021 to 2033 (USD Million)
• 6.4. Laboratories
  • 6.4.1. Laboratories market estimates and forecasts 2021 to 2033 (USD Million)
• 6.5. Others
  • 6.5.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Liver Disease Diagnostics Market: Regional Estimates & Trend Analysis

• 7.1. Regional Dashboard
• 7.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework/ reimbursement structure
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.3.3. Mexico
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework/ reimbursement structure
    • 7.3.3.3. Competitive scenario
    • 7.3.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.6. Norway
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.2. Argentina
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company/Competition Categorization
• 8.2. Strategy Mapping
• 8.3. Company Market Share Analysis, 2023
• 8.4. List of Key Certification Providers/Scheme Owners
• 8.5. Company Profiles/Listing
  • 8.5.1. Abbott
    • 8.5.1.1. Company overview
    • 8.5.1.2. Financial performance
    • 8.5.1.3. Product benchmarking
    • 8.5.1.4. Strategic initiatives
  • 8.5.2. F. Hoffmann-La Roche Ltd.
    • 8.5.2.1. Company overview
    • 8.5.2.2. Financial performance
    • 8.5.2.3. Product benchmarking
    • 8.5.2.4. Strategic initiatives
  • 8.5.3. Thermo Fisher Scientific Inc.
    • 8.5.3.1. Company overview
    • 8.5.3.2. Financial performance
    • 8.5.3.3. Product benchmarking
    • 8.5.3.4. Strategic initiatives
  • 8.5.4. Randox Laboratories Ltd
    • 8.5.4.1. Company overview
    • 8.5.4.2. Financial performance
    • 8.5.4.3. Product benchmarking
    • 8.5.4.4. Strategic initiatives
  • 8.5.5. Boston Scientific Corporation
    • 8.5.5.1. Company overview
    • 8.5.5.2. Financial performance
    • 8.5.5.3. Product benchmarking
    • 8.5.5.4. Strategic initiatives
  • 8.5.6. Laboratory Corporation of America Holdings
    • 8.5.6.1. Company overview
    • 8.5.6.2. Financial performance
    • 8.5.6.3. Product benchmarking
    • 8.5.6.4. Strategic initiatives
  • 8.5.7. Fujifilm Corporation
    • 8.5.7.1. Company overview
    • 8.5.7.2. Financial performance
    • 8.5.7.3. Product benchmarking
    • 8.5.7.4. Strategic initiatives
  • 8.5.8. Horiba Medical
    • 8.5.8.1. Company overview
    • 8.5.8.2. Financial performance
    • 8.5.8.3. Product benchmarking
    • 8.5.8.4. Strategic initiatives
  • 8.5.9. Siemens Healthcare GmbH
    • 8.5.9.1. Company overview
    • 8.5.9.2. Financial performance
    • 8.5.9.3. Product benchmarking
    • 8.5.9.4. Strategic initiatives
  • 8.5.10. Quest Diagnostics
    • 8.5.10.1. Company overview
    • 8.5.10.2. Financial performance
    • 8.5.10.3. Product benchmarking
    • 8.5.10.4. Strategic initiatives